Noopept

Origin and Structure

Noopept is the common name for N-phenylacetyl-L-prolylglycine ethyl ester, also known by its development code GVS-111. It is a small dipeptide-ester prodrug synthesized in 1996 by Tatyana Gudasheva and colleagues at the Institute of Pharmacology of the Russian Academy of Medical Sciences, as part of a program to engineer proline-containing dipeptide fragments that reproduced the cognitive effects of piracetam at a fraction of the dose.

Noopept itself is not highly active; its principal metabolite cycloprolylglycine (cPG) — an endogenous cyclic dipeptide already present in human brain — is thought to carry most of the pharmacology. Noopept's N-phenylacetyl-L-prolylglycine ethyl ester scaffold is effectively a delivery vehicle that survives first-pass metabolism well enough to raise cPG levels in the CNS after oral dosing.

Russian Regulatory Status

Noopept has been registered as a medicine in Russia since 2002 and is sold over-the-counter under the trade name Noopept for asthenic and mild cognitive disorders, post-traumatic cognitive deficits, and post-stroke rehabilitation. It is not approved by the FDA, EMA, Health Canada, or MHRA, and in the United States it is sold only as a research chemical or dietary-supplement-adjacent ingredient with no recognized regulatory category.

Mechanism of Action

The mechanism is multi-layered and not fully resolved, but three threads recur across the literature:

• AMPA and TrkB modulation. The cPG metabolite behaves as a positive modulator of AMPA-type glutamate receptors and appears to engage BDNF/TrkB signaling, a combination that maps onto long-term potentiation and synaptic plasticity.
• Antioxidant and anti-apoptotic activity. Cell-culture work has documented protection of cortical neurons from oxidative damage and apoptosis, including in Down-syndrome-derived neuronal lines.
• NGF and BDNF upregulation. Chronic dosing in rodents raises hippocampal expression of both major neurotrophins — the pattern most often invoked to explain cognitive improvements after repeated use.

Clinical Evidence

Most human data is Russian. Published trials include small controlled studies in asthenic syndrome, post-concussive cognitive impairment, mild cerebrovascular disease, and cognitive decline in older adults. Effect sizes are modest but consistent: improvement on attention, working memory, and subjective fatigue scales, with placebo-controlled separations typically appearing after 14–28 days of dosing rather than acutely.

Methodological caveats mirror those of the broader Russian nootropic literature: small sample sizes, limited blinding detail, sparse independent replication, and almost no presence in the major English-language pharmacology journals. Western systematic reviews have generally classified noopept as "plausible but not established."

Practical Considerations

Russian clinical dosing is typically 10 mg twice daily, taken with or after food, for courses of 4–8 weeks, occasionally extended to 12. Onset of subjective effects is usually reported over 1–2 weeks — noopept is not an acute stimulant in the caffeine sense, and expectations set by single-dose trials tend to disappoint. The compound is orally bioavailable (a rarity for peptides of any kind) and does not require reconstitution.

Noopept is often discussed alongside other Russian-school cognitive peptides — see our Semax reference and Selank reference for two intranasal compounds that occupy adjacent niches. Unlike those, noopept is a small-molecule prodrug and does not require injection or nasal spray.

Safety Profile

Decades of over-the-counter Russian use have produced a generally benign adverse-event picture: mild headache, occasional irritability or sleep disturbance at higher doses, and rare GI upset. No significant cardiovascular, hepatic, or endocrine toxicity signals have emerged. Noopept is not on the WADA prohibited list. It should not be combined casually with other glutamatergic or serotonergic compounds without medical supervision.

The Bottom Line

Noopept is one of the better-characterized Russian nootropics, with a credible mechanism (cPG-mediated AMPA/TrkB engagement), real — if modest — human trial data, and a long safety record under OTC use. It is also almost invisible in Western regulatory frameworks, which means supply-chain quality and dose accuracy are the practical limiting factors outside Russia. For a synthesis of where this cluster of compounds sits versus Western cognitive drugs, see our broader peptide research landscape coverage.